Pharma Deals Review, Vol 2010, No 9 (2010)

Font Size:  Small  Medium  Large

GSK Obtains Exclusive Rights to Amicus Therapeutics’ Drug for Fabry Disease

Editorial Team

Abstract


GlaxoSmithKline has licenced Amigal™, a late stage treatment for the rare disorder Fabry disease. GSK will pay USD 61 M upfront for the licence and 19.9% equity, with USD 170 M to follow as development and commercialisation milestones.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.